BridgeBio advances launch plans for infigratinib and BBP-418
BridgeBio Pharma says it is advancing launches of infigratinib and BBP-418, issuing inducement RSUs to new hires, and targeting profitability by 2027, while warning regulatory and pricing changes could affect plans.